Recursion Pharmaceuticals clinical trials
Recursion Pharmaceuticals is the lead sponsor of 4 current clinical trials in our USA, Canada and EU (CTIS) registers. 3 are recruiting patients now. All registered phases are Phase 1/2. The most-studied condition is Familial Adenomatous Polyposis.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Recursion Pharmaceuticals
3 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
NCT05552755 · Familial Adenomatous Polyposis
|
Phase 1/2 | Recruiting | 2023-07 | USA |
|
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659 · Unresectable, Locally Advanced, Metastatic Cancers
|
Phase 1/2 | Recruiting | 2024-11 | USA, Canada |
|
REC-7735 in Participants With Solid Tumors
NCT07819136 · Solid Tumors
|
Phase 1/2 | Recruiting | 2026-09 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Recursion Pharmaceuticals in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System with Recursion Pharmaceuticals as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)
2026-525282-50-00 · Neoplasms
|
Phase 2 | Authorised | Netherlands, Germany, Spain |
Conditions in Recursion Pharmaceuticals trials
6 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 3 |
| Clinical trials in Canada | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
Questions about Recursion Pharmaceuticals trials
How many clinical trials does Recursion Pharmaceuticals sponsor?
Recursion Pharmaceuticals is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA and Canada registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Recursion Pharmaceuticals trials recruiting?
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.